AgriFORCE Growing Systems Ltd. to Participate in Exclusive BitGo-Hosted Events at Bitcoin 2025; CEO Jolie Kahn Recognized as One of the Only Female Public Company Leaders in Bitcoin Mining
Vancouver, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) — AgriFORCE Growing Systems Ltd. ('AgriFORCE' or the 'Company') (NASDAQ: AGRI), a diversified technology and infrastructure company, today announced its participation in a curated series of private events hosted by BitGo during Bitcoin 2025, the world's largest Bitcoin conference, taking place May 27–29 at The Venetian Resort in Las Vegas, Nevada.
AgriFORCE CEO Jolie Kahn will attend four exclusive BitGo-hosted gatherings over the course of the week, including: BitGo High Roller Summit (May 27–29): An invite-only, three-day experience for top-tier institutions, builders, and visionaries in the Bitcoin space, featuring high-level networking, strategic dialogues, and exclusive access to VIP forums.
(May 27–29): An invite-only, three-day experience for top-tier institutions, builders, and visionaries in the Bitcoin space, featuring high-level networking, strategic dialogues, and exclusive access to VIP forums. BitGo x A&T Capital After Dark Party (May 28): An evening celebration blending deal-making and community engagement with entertainment and cultural activations tailored for global crypto leaders. Event link
(May 28): An evening celebration blending deal-making and community engagement with entertainment and cultural activations tailored for global crypto leaders. BitGo Institutional Sunset Soirée (May 29): A sunset rooftop gathering that brings together the most influential players in digital asset custody, capital allocation, and infrastructure strategy. Event link
(May 29): A sunset rooftop gathering that brings together the most influential players in digital asset custody, capital allocation, and infrastructure strategy. 2025 Women of Bitcoin Brunch (May 27): Hosted by Bitcoin Magazine and BitGo, this premier networking brunch celebrates the leadership and contributions of women in the Bitcoin industry. Event link
As a guest of BitGo, Ms. Kahn's participation underscores her growing influence in the energy-powered digital infrastructure sector. Importantly, Jolie Kahn is among a very limited number—if not the only —female CEOs leading a publicly traded company actively engaged in Bitcoin mining. Her presence at Bitcoin 2025 signals AgriFORCE's commitment not only to innovation and sustainability but also to advancing diversity and inclusion at the highest levels of industry leadership.
'It's an honor to represent AgriFORCE and our TerraHash Digital™ platform at Bitcoin 2025 alongside some of the most respected minds in Bitcoin and digital infrastructure,' said Jolie Kahn, CEO of AgriFORCE. 'As a female CEO in the Bitcoin mining space—a rare position—I'm proud to contribute a unique perspective to a field that's still in the early stages of building true inclusivity. We're here to do big things: responsibly, profitably, and with purpose.'
Strategic Presence at Bitcoin 2025
AgriFORCE's attendance at these events complements its recent launch of TerraHash Digital™, a wholly owned division focused on vertically integrated, energy-efficient Bitcoin mining campuses. The Company's participation reflects its goal of leading from the front—building next-generation infrastructure that is both sustainable and inclusive.
About AgriFORCE Growing Systems Ltd.
AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) is a mission-driven technology company pioneering innovation at the intersection of agriculture, clean energy, and digital infrastructure. Through its TerraHash Digital™ division, the Company is building high-performance Bitcoin mining campuses with dual-purpose utility—supporting decentralized compute networks while enabling clean energy reuse and sustainable food production.
About BitGo
BitGo is the leading infrastructure provider of digital asset solutions, delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. Since our founding in 2013, we have focused on enabling our clients to securely navigate the digital asset space. With a large global presence through multiple regulated entities, BitGo serves thousands of institutions, including many of the industry's top brands, exchanges, and platforms, as well as millions of retail investors worldwide. As the operational backbone of the digital economy, BitGo handles a significant portion of Bitcoin network transactions and is the largest independent digital asset custodian, and staking provider, in the world. For more information, visit www.bitgo.com .
IG (Instagram): @agriforcegs
X (Twitter): @agriforcegs
FB (Facebook): @agriforcegs
LinkedIn: @agriforcegs
TruthSocial: @agriforcegs
Follow TerraHash Digital™ on Social Media:
IG (Instagram): @Terrahashdigital
X (Twitter): @THashDGTL
FB (Facebook): TerraHash Digital™
LinkedIn: @TerraHash-Digital
TruthSocial: @THashDGTL
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These include, but are not limited to, statements regarding expected operational capabilities, project development, and financial or environmental impacts. Such forward-looking statements involve risks and uncertainties, including those beyond the Company's control, and may cause actual results to differ materially. Readers are advised to review the Company's filings with the SEC under the heading 'Risk Factors' in Forms 10-K, 10-Q, and 8-K. AgriFORCE undertakes no obligation to update forward-looking statements due to new information or future developments.
For more information, visit: www.agriforcegs.com
Investor Relations: 1-561-717-1742
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Junee Limited 宣佈完成公司名稱變更為 SuperX AI Technology Limited，並開始以新股票代碼「SUPX」進行交易
新加坡2025年6月2日 /美通社/ -- 在納斯達克上市的公司 Junee Limited（NASDAQ: JUNE）今天宣佈，已完成之前宣佈的公司名稱變更和品牌重塑，現更名為 SuperX AI Technology Limited（「SuperX」或「公司」）。與名稱變更相關，公司普通股將於今天在納斯達克資本市場以新股票代碼「SUPX」開始交易。品牌重塑反映了公司向一站式人工智慧基礎設施解決方案提供商的戰略轉型。新企業網站現已上線，網址為 此次企業品牌重塑體現了公司向一站式人工智慧（AI）基礎設施解決方案提供商的戰略轉型。公司計畫開發和交付包括計算、模型託管、資料管道和編排工具在內的綜合系統，以支援全球企業的人工智慧部署。 「這一轉變標誌著我們增長戰略中的一個重要里程碑，」SuperX 執行董事余俊傑表示。「我們的新名稱更準確地反映了我們賦能開發者、企業和研究機構的長期願景，提供可擴展的高性能基礎設施，以適應人工智慧時代。」 名稱變更不會影響股東的權利，當前股東無需採取任何行動。公司普通股的 CUSIP 號碼將保持不變。 關於 SuperX AI Technology Limited: SuperX AI Technology Limited（NASDAQ: SUPX）是一家專注於提供高品質住宅和商業室內設計解決方案的公司。通過其子公司，包括 MindEnergy AI Technology Pte. Ltd. 和 ASPAC AI Computing Pty Ltd，SuperX 旨在成為一家領先的技術公司，致力於開發和交付下一代數位基礎設施解決方案。公司致力於將智慧技術整合到其產品的各個方面，為行業設定創新和卓越的新標準。 本新聞稿包含前瞻性聲明，涉及風險和不確定性。實際結果可能因各種因素與這些前瞻性聲明所指示的結果存在重大差異。建議投資者查閱 SuperX AI Technology Limited 向證券交易委員會提交的檔，包括最新的 20-F 表格，以討論這些風險和不確定性。 View original content: SOURCE SuperX AI Technology Limited
Yahoo
26 minutes ago
- Yahoo
Interventional Pulmonology Device Market Valued at $6.2B in 2024, Forecast to Exceed $10B by 2034
Interventional Pulmonology Device Market Report (2025–2034) Luton, Bedfordshire, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Market Overview The global interventional pulmonology device market is projected to reach USD 6.2 billion in 2024 and is expected to exceed USD 10 billion by 2034, growing at a CAGR of approximately 6.3%. The market's expansion is primarily driven by: The increasing prevalence of respiratory diseases A growing geriatric population Technological advancements in minimally invasive pulmonary procedures Get a Sample PDF Brochure: Key Market Drivers (Detailed) Rising Incidence of Respiratory Conditions Chronic Obstructive Pulmonary Disease (COPD) affects over 390 million people globally, with high prevalence in aging and smoking populations. Asthma cases are steadily rising, especially among children and in urban settings due to pollution. Lung cancer, often diagnosed late, requires advanced bronchoscopic biopsies—driving demand for diagnostic tools and navigation systems. Aging Population As global life expectancy increases, so does the aging population (65+), who are more susceptible to respiratory diseases due to declining lung function. Geriatric patients require minimally invasive diagnostic and therapeutic options, such as robotic-assisted bronchoscopy and cryotherapy tools. Innovation in Bronchoscopic Technologies Robotic-assisted bronchoscopy (e.g., Ion by Intuitive Surgical) allows for precise navigation into peripheral lung lesions. AI-powered imaging systems help detect lesions, assist in real-time decision-making, and reduce false negatives. Integration with 3D imaging and electromagnetic navigation improves procedural success rates. Favorable Regulatory Trends Agencies like the FDA and EMA are expediting approvals for innovative minimally invasive devices. Coverage expansion by insurance companies for bronchial thermoplasty and navigational bronchoscopy is encouraging adoption. Increased government grants and public-private partnerships supporting lung cancer screening programs. Market Challenges (Detailed) High Procedure Costs Advanced equipment like robotic bronchoscopes and navigation systems cost hundreds of thousands of dollars. Limited adoption in developing nations and smaller hospitals due to high capital and maintenance costs. Reimbursement Complexities Variability in insurance coverage across countries creates uncertainty for providers and patients. Some emerging procedures lack proper coding or are not included in standard coverage schemes, hampering widespread use. Regulatory Hurdles Interventional pulmonology devices often face long and expensive clinical trial requirements, particularly for Class III devices. Cross-border regulatory harmonization remains a challenge for manufacturers expanding globally. Supply Chain Disruptions The COVID-19 pandemic revealed fragility in global supply chains—impacting availability of scopes, catheters, and components. Ongoing geopolitical tensions, raw material shortages, and dependency on single-source suppliers remain key risks. Growth Opportunities (Detailed) AI & Smart Bronchoscopy Devices Companies are integrating machine learning algorithms to analyze real-time bronchoscopic video for better diagnosis. Smart catheters and scopes now include sensors that provide feedback on tissue interaction, force, and navigation. Expanding Use Cases Beyond cancer, bronchoscopic tools are being used for: Infectious disease diagnostics (e.g., TB, fungal infections). Sleep apnea treatment via upper airway stimulation. Interstitial lung disease biopsy with minimal trauma. Growing interest in therapeutic applications like localized drug delivery and stent placement. Surging Healthcare Investments Asia-Pacific is projected to grow at CAGR ~8%, driven by: Increasing government health budgets (India, China). Rapid expansion of private hospitals. Rising awareness about early lung disease detection. Strategic Collaborations Partnerships between device manufacturers and tech firms (e.g., AI developers, imaging companies). Licensing deals and co-development agreements enhancing R&D capabilities. Collaborations with academic institutions accelerating innovation in diagnostics and surgical training tools. Market Segmentation By Product Type The interventional pulmonology devices market is segmented into bronchoscopes, biopsy forceps, endobronchial valves, bronchial dilators, stents, and other devices. Bronchoscopes hold the largest market share, estimated at around 30%, driven by the growing adoption of robotic-assisted systems that allow for enhanced precision, especially in lung cancer diagnostics and treatment. Biopsy forceps account for about 10% of the market, supported by advances that increase tissue sampling accuracy for early cancer detection. Endobronchial valves, making up 15% of the market, are vital for lung volume reduction procedures in COPD patients. Bronchial dilators (20% share) are in high demand due to their role in airway stenosis management. Stents contribute approximately 12% of the market, with innovations such as self-expanding and drug-eluting designs driving their growth. The remaining 13% includes various specialized tools like navigational aids, cryoprobes, and catheters, used in advanced diagnostic and therapeutic interventions. Product Type Estimated Share (%) Key Trends Bronchoscopes 30% Increasing adoption of robotic systems Biopsy Forceps 10% Enhanced precision in lung cancer diagnostics Endobronchial Valves 15% Key in lung volume reduction procedures Bronchial Dilators 20% Demand driven by airway management needs Stents 12% Innovations in self-expanding and drug-eluting designs Other Devices 13% Includes navigational aids and catheters By Application In terms of application, oncology represents the largest segment, accounting for around 45% of the market. This dominance is attributed to the rising global burden of lung cancer and the increasing use of bronchoscopy for early detection, biopsy, and treatment. Respiratory diseases, including COPD and asthma, follow with a 30% share, fueled by aging populations and increasing environmental risk factors. Infectious diseases, such as tuberculosis and pneumonia, make up 15% of the market, with flexible bronchoscopy playing a central role in accurate diagnosis and treatment. Sleep apnea, with a 10% share, is an emerging application area benefiting from growing awareness, diagnostics, and minimally invasive interventional therapies such as airway stimulation and dilation. Application Share (%) Notes Oncology 45% Lung cancer diagnostics and treatment Respiratory Diseases 30% Includes COPD, asthma Infectious Diseases 15% TB, pneumonia diagnostics Sleep Apnea 10% Growing with increasing diagnosis rates By End User Hospitals dominate the end user segment, accounting for approximately 60% of all procedures, owing to their comprehensive infrastructure, skilled personnel, and capacity for high procedure volumes. Ambulatory Surgical Centers (ASCs) follow with a 20% share, driven by the rising demand for outpatient bronchoscopy and cost-effective care settings. Specialty clinics, comprising around 10%, cater to respiratory and oncology-specific needs with dedicated technologies and expertise. Research institutions, although a smaller segment at 5%, play a crucial role in clinical trials, device development, and the early adoption of cutting-edge bronchoscopy technologies. End User Share (%) Hospitals 60% Ambulatory Surgical Centers (ASCs) 20% Specialty Clinics 10% Research Institutions 5% By Procedure Type Based on procedure type, diagnostic procedures lead the market with a 40% share, supported by the increasing need for accurate detection of lung cancer, infections, and airway obstructions through advanced biopsy and imaging-guided tools. Therapeutic procedures hold a 35% share and include treatments such as stenting, cryotherapy, and laser ablation to manage airway tumors or strictures. Surgical procedures account for 25% of the market and are expanding in scope with the introduction of robotic-assisted bronchoscopy, allowing safer and more precise access to peripheral lung lesions. Procedure Type Share (%) Diagnostic 40% Therapeutic 35% Surgical 25% By Technology Technologically, flexible bronchoscopy remains the most widely used approach, preferred for its versatility in both diagnostic and therapeutic settings. Rigid bronchoscopy, although more invasive, is crucial in complex therapeutic interventions such as tumor debulking and managing significant airway obstructions. Robotic-assisted bronchoscopy is the fastest-growing technological segment, offering unparalleled precision in navigating to small or hard-to-reach pulmonary nodules. This innovation is particularly valuable in early-stage cancer diagnosis and is gaining traction among leading hospitals and specialty centers. Flexible Bronchoscopy Rigid Bronchoscopy Robotic-Assisted Bronchoscopy By Distribution Channel The market is distributed through two main channels: direct sales and distributors. Direct sales dominate in large hospitals and integrated health systems, where bulk procurement and customized service agreements are common. Distributors play a critical role in reaching smaller clinics, ASCs, and healthcare providers in emerging markets, helping to bridge supply gaps and expand product accessibility across regions with limited direct manufacturer presence. Direct Sales Distributors By Region Regionally, North America holds the largest share of the interventional pulmonology devices market—approximately 45%—fueled by a well-developed healthcare infrastructure, high prevalence of respiratory conditions, and early adoption of advanced technologies such as robotic bronchoscopy. Europe follows with significant market presence due to strong healthcare systems and a growing preference for minimally invasive pulmonary interventions. The Asia-Pacific region is the fastest-growing, with an estimated CAGR of 8%, driven by rapid urbanization, rising healthcare investments, and increasing incidence of respiratory diseases. Latin America is witnessing steady growth as awareness programs and public health initiatives improve access to care. Meanwhile, the Middle East & Africa region is emerging as a promising market, with expanding healthcare services and a rising burden of respiratory infections contributing to increased demand for interventional pulmonology solutions. Region Key Highlights North America 45% of market share, driven by advanced healthcare infrastructure Europe Strong focus on minimally invasive solutions Asia-Pacific Fastest growth due to healthcare reforms and investment Latin America Gradual adoption, driven by public health campaigns Middle East & Africa Emerging opportunities amid rising respiratory disease burden Browse full Report - Key Players · Medtronic plc · Boston Scientific Corporation · Johnson & Johnson (Ethicon, Inc.) · Olympus Corporation · Siemens Healthineers AG · AngioDynamics Inc. · Teleflex Incorporated · Cook Medical LLC · ConMed Corporation · Merit Medical Systems, Inc. · C.R. Bard, Inc. (Becton, Dickinson and Company) · Neuwave Medical (Johnson & Johnson subsidiary) · Hologic, Inc. · Asahi Intecc Co., Ltd. · Lumenis Ltd. · Smiths Medical (ICU Medical) · FUJIFILM Holdings Corporation · KARL STORZ SE & Co. KG · Broncus Medical, Inc. · Veran Medical Technologies Recent Developments: · Medtronic: In December 2023, Medtronic announced a collaboration with Cosmo Pharmaceuticals to integrate artificial intelligence into endoscopic procedures. This partnership aims to enhance diagnostic accuracy and patient outcomes in interventional pulmonology. · Boston Scientific Corporation: In November 2023, Boston Scientific completed the acquisition of Relievant Medsystems, Inc., expanding its portfolio in interventional pain management solutions. This acquisition adds the Intracept® system, a minimally invasive treatment for vertebrogenic pain, to Boston Scientific's offerings. · Johnson & Johnson (Ethicon): In June 2023, Ethicon entered a strategic partnership with a technology firm specializing in AI-driven pulmonary diagnostics. This collaboration focuses on developing advanced solutions to improve the accuracy and efficiency of lung disease diagnosis. · Olympus Corporation: In September 2023, Olympus launched enhancements to its endoscopic imaging systems, incorporating augmented reality features. These advancements aim to improve visualization and precision during interventional pulmonology procedures. · Teleflex Incorporated: In October 2023, Teleflex received regulatory approval for its innovative bronchial intervention device designed for patients with severe asthma. This approval allows Teleflex to address a significant unmet need in asthma management. This report is also available in the following languages : Japanese (インターベンショナル肺疾患デバイス市場), Korean (중재적 폐의학 기기 시장), Chinese (介入性肺病学设备市场), French (Marché des dispositifs de pneumologie interventionnelle), German (Markt für interventionelle Pulmonologiegeräte), and Italian (Mercato dei dispositivi di pneumologia interventistica), etc. Get a Sample PDF Brochure: More Research Finding – Interventional Lung Solutions MarketThe interventional lung solutions market is projected to reach a value of approximately $3.2 billion in 2024, driven by rising lung disease prevalence and advancements in medical technologies. Forecasts indicate a substantial growth trajectory, with the market anticipated to expand at a Compound Annual Growth Rate (CAGR) of 7.5% from 2025 to 2034, potentially reaching around $6 billion by U.S. Disposable Endoscope MarketThe U.S. disposable endoscope market is projected to reach approximately $1.2 billion in 2024, driven by increasing demand for minimally invasive procedures and heightened awareness of infection control. The market is forecasted to expand significantly, with an expected value of $3.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 11.4% during the 2025–2034 Bronchoscopy MarketThe global bronchoscopy market is valued at approximately $3.5 billion in 2024, with projections indicating substantial growth to around $5.9 billion by 2034. This reflects a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to Bronchoscopes MarketThe global bronchoscopes market size is to be valued at USD 42.29 billion by 2029 and is expected to grow at a compound annual growth rate (CAGR) of 8.3% during the forecast period. Colonoscopy Devices MarketThe global colonoscopy devices market is valued at approximately $2.5 billion in 2024 and is projected to reach around $4 billion by 2034, demonstrating a robust Compound Annual Growth Rate (CAGR) of 4.7% over the forecast period from 2025 to Fluorescence Endoscopy System MarketThe global fluorescence endoscopy system market is valued at approximately $1.2 billion in 2024 and is projected to reach $2.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.6% during the forecast period from 2025 to 2034. Disposable Coaxial Biopsy Needle MarketThe global market for disposable coaxial biopsy needles is valued at approximately $600 million in 2024, driven by an increasing demand for minimally invasive diagnostic procedures. It is projected to reach around $900 million by 2034, reflecting significant growth opportunities. The estimated Compound Annual Growth Rate (CAGR) during the forecast period of 2025 to 2034 is approximately 4.3%, influenced by advancements in imaging technologies and rising awareness of early cancer Endoscope Optics Objective MarketThe global endoscope optics market is valued at approximately $5.1 billion in 2024, with projections indicating a substantial increase to around $8.2 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 5.0% for the forecast period (2025–2034). Single Use Video Endoscope MarketThe global single-use video endoscope market is poised for significant growth, valued at approximately $2.1 billion in 2024. Projections suggest an increase to around $4.8 billion by 2034, driven by rising demand for minimally invasive procedures and advancements in endoscopic technology. The Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 8.7%, indicating robust market Fiber Optic Endoscope MarketThe global fiber optic endoscope market is valued at approximately $2.6 billion in 2024 and is projected to reach around $4.5 billion by 2034, reflecting significant growth opportunities. This translates to a Compound Annual Growth Rate (CAGR) of about 6.2% during the forecast period from 2025 to Medical Endoscopy Equipment MarketThe global medical endoscopy equipment market is valued at approximately $46 billion in 2024, with projections indicating growth to around $66 billion by 2034. This translates to a robust compound annual growth rate (CAGR) of 3.8% during the forecast period from 2025 to Ocean Wet Suction Water Seal Chest Drain MarketThe global market for ocean wet suction water seal chest drains is valued at approximately $450 million. This market is expected to grow significantly, projecting a value of around $750 million by 2034. The calculated Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 stands at about 5.4%. Semi-automatic Biopsy Needle MarketThe global semi-automatic biopsy needle market is poised to reach approximately $650 million in 2024, driven by increasing diagnostic procedures and advancements in minimally invasive techniques. The market is projected to grow significantly, with an estimated market value of around $1.1 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to Endoscope Camera System MarketThe global endoscope camera system market is valued at approximately $4.1 billion in 2024, with expectations to reach around $6.9 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 5.5% during the forecast period (2025-2034). Interactive Stethoscope MarketThe global interactive stethoscope market is valued at approximately USD 1.2 billion in 2024, with a projected compound annual growth rate (CAGR) of 12% from 2025 to 2034, anticipating a market value of about USD 3.7 billion by Endoscopic Retrieval Device MarketThe global endoscopic retrieval device market is estimated to reach a value of approximately $1.6 billion in 2024, driven by advancements in minimally invasive surgical techniques and the rising prevalence of gastrointestinal disorders. The market is expected to witness substantial growth, projected to reach around $2.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 6.3% during the forecast period from 2025 to Non-vascular Lumen Guidewire MarketThe global non-vascular lumen guidewire market is valued at approximately $1.2 billion in 2024, with projections for substantial growth over the forecast period (2025–2034), anticipating a market value of $2.4 billion by 2034. This trajectory represents a Compound Annual Growth Rate (CAGR) of around 7.2%. Endoscopic Ultrasound Guided Needles MarketThe global market for endoscopic ultrasound (EUS) guided needles is poised for significant growth, with an estimated value of approximately $330 million in 2024. Projections suggest that the market will reach about $600 million by 2034, reflecting a robust expansion during the forecast period. This growth translates to a Compound Annual Growth Rate (CAGR) of around 6.5% from 2025 to Wireless Endoscopes MarketThe global wireless endoscopy market is valued at approximately $1.2 billion in 2024, with projections indicating a significant rise to around $2.8 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of approximately 9% during the forecast period (2025–2034). CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
HCLTech and UiPath Partner to Accelerate Agentic Automation for Global Enterprises
NEW YORK & NOIDA, India, June 02, 2025--(BUSINESS WIRE)--HCLTech, a leading global technology company, and UiPath (NYSE: PATH), a global leader in agentic automation, today announced a strategic partnership to accelerate agentic automation for UiPath customers globally. The partnership will drive large-scale transformation for enterprises across industries, enabling more intelligent and self-sufficient business process operations that require minimal human intervention. HCLTech will leverage its AI expertise to deploy the UiPath Platform™, enabling autonomous operations in finance, supply chain, procurement, customer service, marketing and human resources. HCLTech will support this partnership with pre-configured AI agents and controls to ensure seamless deployment and scalability. The partnership aims to enhance business agility, optimize workforce efficiency and deliver faster returns on business process automation investments for global enterprises. HCLTech will also establish an AI Lab with UiPath in India to develop Industry Focused Repeatable Solutions (IFRS) and MVPs for the full automation lifecycle, from strategy to implementation and continuous optimization. HCLTech will leverage its global delivery model to support UiPath customers in North America, Europe and Asia-Pacific. "As we shift towards a new era with Agentic AI, agentic automation will be critical to provide businesses with the speed and agility to transform operations and unlock new business potential. Partnering with HCLTech allows UiPath to extend the power of its AI-powered automation to enterprises globally, accelerating intelligent transformation at scale. With HCLTech's deep expertise in AI, automation and industry solutions, UiPath customers will benefit from best-in-class implementation and business impact," said Ashim Gupta, Chief Operating Officer and Chief Financial Officer, UiPath. "By co-creating next-gen AI-powered solutions with UiPath, HCLTech is setting new benchmarks for agentic autonomous operations that unlock unprecedented efficiency, agility and innovation for enterprises. Our proven expertise in hyperautomation, AI and cloud-first architectures helps us provide industry-specific and advanced automation solutions at scale," said Raghu Kidambi, Corporate Vice President and Global Head, Digital Process Operations, HCLTech. About HCLTech HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit About UiPath UiPath (NYSE: PATH) is a global leader in agentic automation, empowering enterprises to harness the full potential of AI agents to autonomously execute and optimize complex business processes. The UiPath Platform™ uniquely combines controlled agency, developer flexibility, and seamless integration to help organizations scale agentic automation safely and confidently. Committed to security, governance, and interoperability, UiPath supports enterprises as they transition into a future where automation delivers on the full potential of AI to transform industries. For more information, visit View source version on Contacts For more information, please contact:HCLTechMeredith Bucaro, Americasmeredith-bucaro@ Elka Ghudial, James Galvin, Nitin Shukla, Indianitin-shukla@ UiPathMedia Contactpr@ Investor Relations
